Can high-flying growth justify a premium valuation, or is a recovered value play the safer bet for 2026? Investors are weighing Eli Lilly and (NYSE:LLY) against Teva Pharmaceutical Industries (NYSE:TEVA) today Eli Lilly dominates the innovative brand-name drug marke
Investors comparing the iShares S&P Small-Cap 600 Growth ETF (NASDAQ:IJT) and the Invesco S&P SmallCap 600 Pure Growth ETF (NYSEMKT:RZG) must weigh the significantly lower ownership costs of the iShares fund against the Invesco fund's stronger recent 1-year total return. B
Amazon, Google, Microsoft, and Meta invest in proprietary silicon as Nvidia’s Q1 data center sales hit $75.25 billion. Nvidia reported Q1 FY27 revenue of $81.61 billion, up 85.2% year over year, driven by $75.25 billion in data center sales. However, half of those sales co
Retail stocks can make for attractive long-term investments due to their stability and continued growth over the years. These businesses may not be high-growth machines, but many of them can be counted on for consistent single-digit growth and are relatively safe options t
Goldman Sachs raised its JBLU price target citing resilient travel demand and declining fuel prices ahead of Q2 earnings. Goldman Sachs increased its price target for JetBlue Airways Corporation (NASDAQ:JBLU) to $4.50 from $3.50 while maintaining a Sell rating. The adjustm
American Airlines receives upgraded price targets from two major firms amid resilient travel demand and fare increases. TD Cowen raised its price target for American Airlines Group Inc. (NASDAQ:AAL) to $24 from $20, maintaining a Buy rating ahead of second-quarter earnings
Barclays downgrades Dana Incorporated to Equal Weight and lowers its price target amid acquisition-related near-term valuation concerns. Barclays reduced its price target for Dana Incorporated (DAN) to $33 from $41 and downgraded the stock to Equal Weight from Overweight.
Analysts raised UNFI targets to $56 and $47 following stronger-than-expected third-quarter results and productivity gains. United Natural Foods (UNFI) saw its price targets raised by BMO Capital and Goldman Sachs after reporting third-quarter earnings that exceeded forecas
Viridian Therapeutics sets Lumvoa at $450,000 per course, matching Tepezza pricing, as analysts raise price targets. Wedbush raised its price target on Viridian Therapeutics (NASDAQ:VRDN) to $43 from $32, maintaining an Outperform rating after the FDA approved Lumvoa. The
UBS raises Clover Health's price target by 73% citing 51.31% projected EPS growth over five years and improving profitability. UBS analyst Jonathan Yong increased Clover Health Investments Corp.'s (NASDAQ:CLOV) price target to $4.75 from $2.75, maintaining a Neutral rating
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.